Question 4

Nitroglycerin SL is exempt from the Poison Prevention Packaging Act.

Nitroglycerin sublingual (SL) tablets are specifically exempt from the requirements of the Poison Prevention Packaging Act due to their unique therapeutic use and the need for rapid access in emergencies.

A) Nitroglycerin SL

This option is correct as nitroglycerin SL is explicitly exempt from child-resistant packaging requirements under the Poison Prevention Packaging Act. The exemption is granted because nitroglycerin is often used for acute angina attacks, and patients need immediate access to the medication.

B) Atenolol

Atenolol is not exempt from the Poison Prevention Packaging Act. It is a prescription medication used to treat high blood pressure and other cardiovascular conditions, and it requires child-resistant packaging to prevent accidental ingestion by children.

C) Amoxicillin

Amoxicillin is also not exempt from the Poison Prevention Packaging Act. As a commonly prescribed antibiotic, it is essential to package it in a child-resistant manner to minimize the risk of accidental poisoning among children.

D) Glipizide

Glipizide, which is used to manage blood sugar levels in diabetes, is similarly not exempt from the Poison Prevention Packaging Act. Like many oral medications, it is necessary to package glipizide in child-resistant containers to protect children from potential harm.

Conclusion

In summary, nitroglycerin SL is the only medication listed that is exempt from the Poison Prevention Packaging Act due to its critical use in emergency situations. The other options, atenolol, amoxicillin, and glipizide, must be packaged in child-resistant containers to ensure safety and prevent accidental ingestion by children. This highlights the importance of tailoring packaging requirements based on the specific use and risks associated with each medication.